Literature DB >> 25817102

Retrospective review of serum and urinary lithogenic risk factors in patients with osteoporosis and osteopenia.

Miguel Angel Arrabal-Polo1, María Sierra Girón-Prieto2, María Del Carmen Cano-García3, Antonio Poyatos-Andujar4, Miguel Quesada-Charneco5, Felix Abad-Menor6, Salvador Arias-Santiago7, Armando Zuluaga-Gomez6, Miguel Arrabal-Martin6.   

Abstract

OBJECTIVE: To analyze differences in bone remodeling markers, lithogenic factors and bone densitometry among the 3 groups of patients (controls, patients with relapsing calcium renal lithiasis, and patients with loss of bone mineral density without lithiasis).
MATERIAL AND METHODS: This is a cross-sectional study including 203 patients who were divided in 3 groups: group 1 (controls), group 2 (patients with relapsing calcium renal lithiasis), and group 3 (patients with osteopenia and/or osteoporosis in the lumbar spine or hip). Bone densitometry, calcium-phosphorous and bone metabolism analysis, and analysis of lithogenic risk factors in fasting urine samples and 24-hour urine samples were performed. Statistical analysis was performed with SPSS 17.0. A P ≤.05 was considered statistically significant.
RESULTS: Patients in group 2 presented greater calcium excretion and a lower citrate excretion in 24-hour urine samples as compared with the other 2 groups. The proportion of hypercalciuria and hypocitraturia was higher in group 2. In addition, patients in group 2 presented a lower loss of bone mineral density as well as altered bone remodeling markers as compared with those in group 1. Patients in group 3 also presented alterations in urine calcium and citrate excretion with respect to the control group, with elevated fasting calcium and citrate levels and calcium-to-citrateratio.
CONCLUSION: Lithogenic risk factors are altered in patients with osteopenia and/or osteoporosis without renal lithiasis although to a lesser extent than patients with calcium renal lithiasis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25817102     DOI: 10.1016/j.urology.2015.01.019

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

Review 1.  Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis.

Authors:  P Lucato; C Trevisan; B Stubbs; B M Zanforlini; M Solmi; C Luchini; G Girotti; S Pizzato; E Manzato; G Sergi; S Giannini; M Fusaro; N Veronese
Journal:  Osteoporos Int       Date:  2016-06-11       Impact factor: 4.507

2.  Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis.

Authors:  Yuanxin Liu; Guilai Zuo; Xin Meng; Xingxiao Gao; Lihai Zhang; Peifu Tang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

Review 3.  Role of Citrate in Pathophysiology and Medical Management of Bone Diseases.

Authors:  Donatella Granchi; Nicola Baldini; Fabio Massimo Ulivieri; Renata Caudarella
Journal:  Nutrients       Date:  2019-10-25       Impact factor: 5.717

4.  Low bone mineral density is a potential risk factor for symptom onset and related with hypocitraturia in urolithiasis patients: a single-center retrospective cohort study.

Authors:  Kazumi Taguchi; Shuzo Hamamoto; Atsushi Okada; Yutaro Tanaka; Teruaki Sugino; Rei Unno; Taiki Kato; Ryosuke Ando; Keiichi Tozawa; Takahiro Yasui
Journal:  BMC Urol       Date:  2020-10-29       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.